Signalling by interferon (IFN) affects COVID-19 pathology in both protective and harmful ways. A multi-omics biosignature associated with varying levels of 12 different type I, II, and III IFNs has been defined in a systemic IFN signalling in hospitalized COVID-19 patients. This evidence concerns the gene IFNA1 and COVID-19.